The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, ...

Androgen deprivation therapy (ADT) – also called hormone therapy - remains central to prostate cancer care, but emerging treatments like radioisotopes and antibody therapies may reduce reliance on ...

Discover a study uncovering epigenetic drivers of resistance to enzalutamide in metastatic prostate cancer and potential ...

Care partners play a vital role in helping prostate cancer patients navigate complex treatment decisions, especially during ...

Early detection of prostate cancer is critical, and researchers are developing a new urine test that may improve accuracy ...

Sir Chris Hoy has never been one to blow his own trumpet. Even at the peak of his career, when he was hoovering up Olympic ...

In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

Northwestern Medicine investigators have discovered a new combination approach that may improve the efficacy of MYC inhibitor drugs for treating aggressive and treatment-resistant cancers, according ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

If confirmed, our findings may provide a more precise clinical target for definitive trials of PA as a prostate cancer treatment as well as for PA promotion efforts in newly diagnosed prostate cancer ...

Chicago Cubs great Ryne Sanberg faced prostate cancer with grace and openness. His goal was to help others. From the ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.